viewLexagene Hldgs Inc.

LexaGene hits major milestone, places its pathogen-detecting technology in major Massachusetts veterinary hospital

The beta prototype identifies the presence of bacteria causing urinary tract infections in animals and screens samples for common antibiotic resistance factors so vets can make treatment decisions

dog and cat
The prototype was placed at Massachusetts Veterinary Referral Hospital, part of a US-wide network

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Wednesday that a major veterinary hospital in Massachusetts will house the first beta prototype of the company’s LX Analyzer.

The beta prototype identifies the presence of bacteria causing urinary tract infections in animals and screens samples for common antibiotic resistance factors so that veterinarians have the correct information to select the best course of treatment.

LexaGene's shares jumped 9.5% at C$0.69 in Toronto on Wednesday morning and 15.3% at US$0.52 on OTC markets.

READ: LexaGene Holdings completes development of antibiotic resistance marker panel

Massachusetts-based LexaGene said the prototype had been placed at Massachusetts Veterinary Referral Hospital, which is among 24 hospitals owned by Ethos Veterinary Health, a US network of veterinary hospitals providing specialty and emergency care for pets.

“This placement marks a very significant milestone for the company and for the diagnostics industry,” said Dr Jack Regan, LexaGene’s founder and CEO.

According to Regan, the company selected Mass Vet to be its first site due to their reputation for being pioneers and thought leaders in veterinary medicine. “The doctors at Mass Vet are eager to test our cutting-edge technology to provide the best possible treatment for their patients,” he said.

LexaGene said it will continue placing devices at various other sites throughout the US as part of an ongoing beta test program.

“This will enable potential customers to experience the technology in their own facility so that they can compare LX-generated results to their standard testing methods,” Regan said in a statement. “We are confident these users will quickly appreciate the benefits of our technology and this will help seed future sales.”

Key features

LexaGene is pioneering the first fully automated pathogen detection platform for use in diagnostics and sample analysis.

The key feature is the open access nature of the instrument that allows end users to customize the instrument to target any pathogen of interest. The instrument is able to process multiple samples at a time, returning results within around one hour.

In addition to veterinary health, LexaGene is initially targeting the food safety industry to detect potential crop-killing pathogens.

--Updates share price--

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Lexagene Hldgs Inc.

Price: 0.67 CAD

Market: TSX-V
Market Cap: $57.39 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Hldgs Inc. named herein, including the promotion by the Company of Lexagene Hldgs Inc. in any Content on the Site, the Company...



Full interview: Lexagene Develops technology to test for deadly mosquito...

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE. Regan says that not only can they use the...

on 09/17/2019

2 min read